Sarah-lee Bekaert

Gent, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

A living biobank of sarcoma patient-derived cell cultures reveals multi-omic and functional insights that capture disease heterogeneity.

A living biobank of sarcoma patient-derived cell cultures reveals multi-omic and functional insights that capture disease heterogeneity.

Journal: Clinical and translational medicine
Published: February 16, 2026

Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma.

Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma.

Journal: Journal of medicinal chemistry
Published: November 18, 2025

Widespread DNA off-targeting confounds RNA chromatin occupancy studies.

Widespread DNA off-targeting confounds RNA chromatin occupancy studies.

Journal: Nature biotechnology
Published: November 11, 2025

Synergistic inhibition of CHK1 and MUS81 to combat replication stress resistance in high-risk neuroblastoma.

Synergistic inhibition of CHK1 and MUS81 to combat replication stress resistance in high-risk neuroblastoma.

Journal: Scientific reports
Published: May 31, 2025

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors.

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors.

Journal: Cell death & disease
Published: May 13, 2025

RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells.

RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells.

Journal: iScience
Published: October 09, 2024

NBAtlas: A harmonized single-cell transcriptomic reference atlas of human neuroblastoma tumors.

NBAtlas: A harmonized single-cell transcriptomic reference atlas of human neuroblastoma tumors.

Journal: Cell reports
Published: February 01, 2024

Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN.

Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN.

Journal: NAR cancer
Published: September 18, 2023

Post-operative minimal residual disease models to study metastatic relapse in soft-tissue sarcoma patient-derived xenografts.

Post-operative minimal residual disease models to study metastatic relapse in soft-tissue sarcoma patient-derived xenografts.

Journal: Clinical and translational medicine
Published: February 15, 2023

Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastoma.

Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastoma.

Journal: iScience
Published: December 20, 2022

Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma.

Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma.

Journal: European journal of medicinal chemistry
Published: August 17, 2022

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.

Journal: Science advances
Published: July 20, 2022
Showing 1-12 of 20

Last Updated: 09/26/2026